Search Immortality Topics:

Page 11,379«..1020..11,37811,37911,38011,381..11,39011,400..»


St. David’s chief gives qualified support to medical school, tax increase

Posted: September 29, 2012 at 3:11 pm

St. Davids HealthCare, the second largest hospital system in Central Texas, has been unusually quiet on the notion of establishing a medical school in Austin.

Executives there also have not spoken out on a proposed tax increase for health care services some of which would go toward underwriting medical school services. On Nov. 6, Travis County voters will decide whether to increase the Central Health portion of the property tax rate from 7.89 cents per $100 of assessed value to 12.9 cents, a 63 percent increase.

Officials at the Seton Healthcare Family, St. Davids chief competitor, have made no secret that they back a medical school, along with a proposed new teaching hospital, upgraded clinics and a comprehensive cancer center championed by state Sen. Kirk Watson, D-Austin. Indeed, Seton has pledged $250 million to build the hospital.

St. Davids President and CEO David Huffstutler serves on a Watson committee working on the projects. In addition, St. Davids is a key partner with Central Health, providing charity care to needy patients and services to Central Healths women patients who want sterilizations, as well as rape victims seeking emergency medication. The Catholic-owned Seton says it cant provide those services. Consequently, St. Davids also trains medical residents on those services and expects that to continue.

Huffstutler discussed these issues with the Statesman on Thursday. An edited version of his remarks follows:

St. Davids has been pretty quiet about the proposed medical school and tax increase on the ballot in November. Are you opposed?

We dont oppose the medical school. Were generally supportive of a medical school. We believe it will be good for economic development. If there is a physican shortage (an argument proponents have made for a medical school), we believe residency slots are more important than undergraduate medical education in getting physicians on the ground in the state. (After the state reduced funding for residency slots) there is obvious concern about supporting those slots. If we dont have the slots, the medical students we educate will leave.

Thats not a rousing endorsement.

I dont know that the way the process has worked has been completely inclusive or completely transparent. While I have been participating on (state Sen. Kirk Watsons) organizing committee, thats not really where the work is being done. We have some questions about how this is all going to work.

What questions?

See the original post:
St. David’s chief gives qualified support to medical school, tax increase

Recommendation and review posted by G. Smith

Patience with late-blooming Homer Bailey pays off in form of Reds' first no-hitter since 1988

Posted: September 29, 2012 at 3:10 pm

Ever a season away from his potential, or a game away, even a pitch away, Homer Bailey on Friday night in Pittsburgh became something like the pitcher the Cincinnati Reds always believed would come with that talented right arm.

On a cool night at PNC Park, near the end of a season in which he became a consistent contributor to and 13-game winner for the NL Central-leading Reds, Bailey threw the modern day record-tying seventh no-hitter of 2012.

After the Pirates' Alex Presley popped out on Bailey's 115th pitch, securing a 1-0 win and the Reds' first no-hitter since Tom Browning's in 1988, Bailey thrust his arms straight over his head and welcomed his onrushing teammates. The Reds' Homer Bailey celebrates after notching the final out in his no-hitter against the Pirates. (AP)

"It's really surreal," Bailey told reporters afterward. "I can't believe it's happening."

In spite of a generation of futility, the Pirates had not been no-hit since 1971 against Bob Gibson. The last Reds right-hander to throw a no-hitter was Tom Seaver, 34 years ago.

[Related: From prospect to priest, ex-A's farm star Grant Desme searches for peace]

Bailey rode his fastball, particularly in Friday night's late innings. His strikeout of pinch-hitter Brock Holt to open the ninth (on a 93-mph fastball) was his 10th, tying his career best. Bailey walked one batter Andrew McCutchen in the seventh inning and had another batter reach on Scott Rolen's fielding error in the third inning. The rest saw Bailey hammer the strike zone with fastballs and bury his slider.

Noting the cooler temperatures and the guidance of catcher Ryan Hanigan, Bailey said, "We didn't have our best stuff, but somehow we were able to go out and make some good pitches."

The seventh overall pick in the 2004 draft, Bailey reached the major leagues three years later, as a 21-year-old. He did not pitch a full season, however, until this one. His career ERA was nearly five when, in April, he began to approach the promise of his early years. Friday's was his 32nd start, during which he surpassed 200 innings for the first time.

As a result, pitching behind Johnny Cueto, Mat Latos and Bronson Arroyo, Bailey is among the reasons the Reds for all intents and purposes finished the NL Central race weeks ago and remain in a fight with the Washington Nationals for the league's best record.

Read the original post:
Patience with late-blooming Homer Bailey pays off in form of Reds' first no-hitter since 1988

Recommendation and review posted by G. Smith

New scholarships for top chemistry grads to teach

Posted: September 29, 2012 at 3:10 pm

-Prestigious 20,000 scholarships to be led by Royal Society of Chemistry - - Government confirms teacher training bursaries for 2013/14 - - New recruitment targets to focus on quality of graduates -

New teacher training scholarships in chemistry led by the Royal Society of Chemistry (RSC) have been announced today.

Around 130 scholarships worth 20,000 each will be available. Any graduate with a 2.1 or first class degree will be eligible to apply for a scholarship on a chemistry Initial Teacher Training (ITT) course.

Working with experts in teaching practice, the RSC will award scholarships to candidates with exceptional subject knowledge, enthusiasm for the study of chemistry, and outstanding potential to teach. The RSCs relationship with the scholars will continue into their teaching careers to develop a cadre of outstanding chemistry teachers who are part of a community of chemists across schools, universities and industry.

The scholarship comes as part of the Governments teacher training strategy, Training our next generation of outstanding teachers, and follows on from the success of the physics scholarship with the Institute of Physics.

Education Secretary Michael Gove said:

If we want to have an education system that ranks with the best in the world, then we need to attract the best people into the profession, and we need to give them outstanding training.

By joining up with the prestigious Royal Society of Chemistry, the scholarship will help make sure we have excellent chemistry teachers in this country with deep subject knowledge. They will help raise the status of the teaching profession and also make a huge difference in the lives of children.

Dr Robert Parker, RSC chief executive, said:

The RSC is delighted to be leading this exciting initiative. We believe passionately in the need for inspirational teaching, and our fervent hope is that this scholarship will increase the number of inspirational chemistry teachers.

Follow this link:
New scholarships for top chemistry grads to teach

Recommendation and review posted by G. Smith

Prana Scientist to Participate in Webcast to Discuss Alzheimer's Disease Therapeutics: Recent Setbacks and Emerging …

Posted: September 29, 2012 at 3:10 pm

MELBOURNE, AUSTRALIA--(Marketwire - Sep 28, 2012) - Prana Biotechnology ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that Chief Scientific Advisor, Rudy Tanzi, Joseph P. and Rose F. Kennedy, Professor of Neurology, Harvard Medical School, will take part in a webcasthosted by George Zavoico, Ph.D., Managing Director and Senior Analyst, of MLV & Co.The topic of the webcast will be: "Alzheimer's Disease Therapeutics: Recent Setbacks and Emerging Alternatives."The webcast will take place on Monday, October 1, at 2:00 pm Eastern Daylight Time (NYC).

The session will consider what are the most promising new technologies for fighting Alzheimer's Disease which, with all other types of dementia, currently affects more than 36 million people worldwide.Participants will hear about innovative technologies and the best way forward for combating Alzheimer's and other age related diseases.Professor Tanzi will address the potential impact of the recent failures of Pfizer's bapineuzumab and Eli Lilly's solanezumab Phase 3 trials and discuss the possible scientific reasons why they did not succeed.

Investors are invited to participate.To obtain dial-in information please contact: Leslie Goedken at 646-556-9206, lgoedken@mlvco.com;or Scott Ammaturo at 646-556-9218, sammaturo@mlvco.com.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at http://www.pranabio.com.

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and otherrisks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Go here to read the rest:
Prana Scientist to Participate in Webcast to Discuss Alzheimer's Disease Therapeutics: Recent Setbacks and Emerging ...

Recommendation and review posted by G. Smith

Biotech Industry Look to Benefit From the Introduction of the High Technology Small Business Research Incentives Act

Posted: September 29, 2012 at 3:10 pm

NEW YORK, NY--(Marketwire - Sep 28, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to the industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on AEterna Zentaris Inc. ( NASDAQ : AEZS ) and Cell Therapeutics Inc. ( NASDAQ : CTIC ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/AEZS

http://www.FiveStarEquities.com/CTIC

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The company recently reported that Fast Track designation had not been granted from the FDA for AEZS-130.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company recently reported positive results from their phase 1 study of its highly selective oral JAK2 inhibitor pacritinib, or SB1518.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

More here:
Biotech Industry Look to Benefit From the Introduction of the High Technology Small Business Research Incentives Act

Recommendation and review posted by G. Smith

Grey's Anatomy Scoop: Jessica Capshaw Discusses Arizona's Fate and What's Next

Posted: September 29, 2012 at 3:10 pm

Jessica Capshaw

[Warning: This story contains major spoilers from the season premiere of Grey's Anatomy. Read at your own risk!]

After spending an entire summer wondering about the fates of our favorite Grey's Anatomy doctors, Thursday's premiere dropped several bombshells that forever changed the staff of Seattle Grace. Cristina (Sandra Oh) moved to Minnesota, Mark (Eric Dane) was pulled off life support, and Arizona (Jessica Capshaw) was missing in action throughout most of the hour.

Missed the season premiere of Grey's Anatomy? Read our recap

The sad truth was that she was at home in bed, destroyed by the fact that not only lives were lost in the plane crash: Her left leg, which was severely injured in the accident, had to be amputated. Yes, the always chipper and bubbly pediatric surgeon who used to roll around the hospital on wheelie shoes is now missing a leg and she blames her wife Callie (Sara Ramirez) for it.

How will Arizona deal with the road ahead? TVGuide.com caught up with Capshaw to get the scoop on that and what this means for Calzona. (Shonda Rhimes, don't you dare break them up!) Get the scoop:

What was your reaction when Shonda told you she was planning to amputate Arizona's leg? Capshaw: I was shocked. I definitely didn't see that one coming. Which, in hindsight seems silly of me given that there was a very, very real and very profound injury at the end of last season, but I just didn't know. I didn't even go there. I guess that's why I don't create shows. [Laughs]

Arizona has always been the pillar of happiness. How dark will her journey go? Capshaw: I think that's the point. There is no light without dark, and there's no dark without light. Yes, at the inception of the character, I think there was something really nice about how light she was. ... Then, ever since going to Africa, when she came back, things just weren't the same. Something happened. It was the car crash. There was the baby. [And now] an airplane crash. She should just walk [out]. Now I say that and look what happened.

What will we see as Arizona is dealing with this? Capshaw: The writers and Shonda are obviously trying to tell good stories. It seems, in the many conversations that we've had, there was a real story here. It was an opportunity to tell a good story of something very profoundly difficult happening to Arizona. Now, we'll see the story of how she comes to terms with that, how long it will be dark, and when it will get light again. Hopefully, it's that whole thing about all the people in London and Seattle: When it rains all the time, that one day that you get that's sunny is like the best day ever. I think that's the idea.

Grey's Anatomy: Where were we and what's next?

See the rest here:
Grey's Anatomy Scoop: Jessica Capshaw Discusses Arizona's Fate and What's Next

Recommendation and review posted by G. Smith


Page 11,379«..1020..11,37811,37911,38011,381..11,39011,400..»